euro adhoc: Sygnis Pharma AG
SYGNIS Pharma AG receives mandatory offer of dievini Hopp BioTech holding GmbH & Co. KG

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- Receipt of mandatory offer 14.11.2008 Ad Hoc Heidelberg, 14 November 2008 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) has been informed today that dievini Hopp BioTech holding GmbH & Co. KG will make a compulsory bid to acquire all shares of SYGNIS Pharma AG at an appropriate price. The detailed conditions for the offer will be announced at a later date. With the compulsory bid dievini Hopp BioTech holding GmbH & Co. KG also fulfils the relevant obligations of the other parties to which the voting rights of dievini Hopp BioTech holding GmbH & Co. KG have to be added. Accordingly, these parties will not make a separate offer. This announcement has to be regarded in the light of SYGNIS Pharma's recent capital increase at the beginning of November in the course of which dievini Hopp BioTech holding GmbH & Co. KG now owns voting rights of approx. 36%. end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: SYGNIS Pharma AG Im Internet recherchierbar: Further inquiry note: Dr. Franz-Werner Haas Vice President Operations Telefon: +49(0)6221 454-812 E-Mail: Branche: Biotechnology ISIN: DE0005043509 WKN: 504350 Index: CDAX Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Hamburg / free trade Börse Stuttgart / free trade Börse Düsseldorf / free trade Börse Hannover / free trade Börse München / free trade

Das könnte Sie auch interessieren: